IL260296B2 - Particles encapsulating fusion proteins containing linked epitopes - Google Patents

Particles encapsulating fusion proteins containing linked epitopes

Info

Publication number
IL260296B2
IL260296B2 IL260296A IL26029618A IL260296B2 IL 260296 B2 IL260296 B2 IL 260296B2 IL 260296 A IL260296 A IL 260296A IL 26029618 A IL26029618 A IL 26029618A IL 260296 B2 IL260296 B2 IL 260296B2
Authority
IL
Israel
Prior art keywords
biodegradable particle
particle
disease
biodegradable
antigen
Prior art date
Application number
IL260296A
Other languages
English (en)
Hebrew (he)
Other versions
IL260296B1 (en
IL260296A (en
Original Assignee
Cour Pharmaceuticals Dev Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cour Pharmaceuticals Dev Company Inc filed Critical Cour Pharmaceuticals Dev Company Inc
Publication of IL260296A publication Critical patent/IL260296A/en
Publication of IL260296B1 publication Critical patent/IL260296B1/en
Publication of IL260296B2 publication Critical patent/IL260296B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL260296A 2016-01-04 2017-01-04 Particles encapsulating fusion proteins containing linked epitopes IL260296B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662274711P 2016-01-04 2016-01-04
PCT/US2017/012173 WO2017120222A1 (en) 2016-01-04 2017-01-04 Particles encapsulating fusion proteins containing linked epitopes

Publications (3)

Publication Number Publication Date
IL260296A IL260296A (en) 2018-08-30
IL260296B1 IL260296B1 (en) 2023-09-01
IL260296B2 true IL260296B2 (en) 2024-01-01

Family

ID=59274014

Family Applications (2)

Application Number Title Priority Date Filing Date
IL260296A IL260296B2 (en) 2016-01-04 2017-01-04 Particles encapsulating fusion proteins containing linked epitopes
IL304580A IL304580A (en) 2016-01-04 2023-07-19 Particles thermalize fusion proteins containing associated epitopes

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL304580A IL304580A (en) 2016-01-04 2023-07-19 Particles thermalize fusion proteins containing associated epitopes

Country Status (6)

Country Link
US (2) US20190365656A1 (https=)
EP (1) EP3400069A4 (https=)
JP (4) JP6904959B2 (https=)
CA (1) CA3009799A1 (https=)
IL (2) IL260296B2 (https=)
WO (1) WO2017120222A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
EP3247384B1 (en) * 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CN111566214B (zh) * 2017-07-06 2024-03-08 日东纺绩株式会社 抗人IgG4单克隆抗体及利用该抗体的人IgG4测定试剂
EP3678677A4 (en) * 2017-09-07 2021-06-16 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
JPWO2019131769A1 (ja) * 2017-12-26 2021-02-12 公立大学法人名古屋市立大学 新規抗ｐａｄ４抗体
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
CN110041408B (zh) * 2018-01-16 2021-05-18 华中科技大学 一种小分子多肽及其在制备防治帕金森综合症药物中的应用
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
JP7523358B2 (ja) * 2018-06-13 2024-07-26 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ ムスカリン受容体ｍ３に対して阻害活性を有するペプチド
US20230001010A1 (en) * 2019-07-19 2023-01-05 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
EP4138907A4 (en) * 2020-04-20 2024-08-21 The General Hospital Corporation IMMUNOGENIC COMPOSITION OF CORONAVIRUS WITH EPITOPES HAVING HIGH NETWORK SCORE
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
IT202000010888A1 (it) * 2020-05-13 2021-11-13 Consiglio Nazionale Ricerche Nanovescicole di mielina e loro impieghi
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
GB202017119D0 (en) * 2020-10-28 2020-12-09 Oxford Vacmedix Uk Ltd Polypeptides for cancer treatment
KR20230171998A (ko) 2021-04-16 2023-12-21 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 면역학적 관용의 유지를 추적하는 방법
JP2024518565A (ja) * 2021-05-11 2024-05-01 オックスフォード ヴァクメディックス ユーケー リミテッド 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤
US20250084126A1 (en) * 2021-07-07 2025-03-13 Osaka University Peptide and composition
WO2023070104A1 (en) 2021-10-21 2023-04-27 Cour Pharmaceuticals Development Company Inc. Treatment of primary biliary cholangitis (pbc) with tolerizing nanoparticles
EP4436557A4 (en) * 2021-11-24 2025-06-11 Cour Pharmaceuticals Development Company Inc. PRODUCTION OF TOLERANT NANOPARTICLES FOR THE TREATMENT OF PEANUT ALLERGY
AU2023238308A1 (en) * 2022-03-24 2024-10-10 Julius-Maximilians-Universität Würzburg Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes
JP2025515424A (ja) 2022-04-29 2025-05-15 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 治療用ベクター及びタンパク質の免疫原性を克服するための寛容化免疫改変ナノ粒子
CN115541872A (zh) * 2022-09-22 2022-12-30 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种pd-l1检测试剂盒及其检测方法
EP4604999A1 (en) 2022-10-19 2025-08-27 Cour Pharmaceuticals Development Company Inc. Treatment of peanut allergy with tolerizing nanoparticles
CN115771883B (zh) * 2022-11-28 2024-02-23 淮阴工学院 从酿酒酵母发酵液中提取的蛋白酶a在化学法合成纳米硒形貌控制和稳定性影响中的用途
TW202444434A (zh) 2023-03-24 2024-11-16 美商庫爾製藥發展公司股份有限公司 用於重症肌無力治療之免疫修飾奈米粒子之處理
KR20260016937A (ko) 2023-05-23 2026-02-04 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 원발성 담즙성 담관염의 치료를 위한 관용화 나노입자의 제조
IL324854A (en) 2023-05-25 2026-01-01 Cour Pharmaceuticals Dev Company Inc Treatment of type 1 diabetes (t1d) with tolerizing nanoparticles
WO2025027015A1 (en) * 2023-08-01 2025-02-06 Diamante Srl Composition and methods for treating multiple sclerosis
WO2025043196A2 (en) * 2023-08-24 2025-02-27 The Trustees Of Indiana University Anti-cancer peptides, and methods and uses thereof
WO2025199149A1 (en) 2024-03-18 2025-09-25 Cour Pharmaceuticals Development Company Inc. Sting agonism for antigen specific tolerance
WO2026019942A2 (en) 2024-07-16 2026-01-22 Cour Pharmaceuticals Development Company Inc. Tolerizing immune modifying nanoparticles for treatment of narcolepsy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032625A1 (en) * 1998-12-04 2000-06-08 Biogen, Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
WO2013122262A1 (en) * 2012-02-16 2013-08-22 Vlp Therapeutics, Llc Virus like particle composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020131960A1 (en) * 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
EP2571992B1 (en) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
JP2013538211A (ja) * 2010-08-23 2013-10-10 セレクタ バイオサイエンシーズ インコーポレーテッド 抗原に対する免疫反応を誘発する標的マルチエピトープ剤形
CN110064049B (zh) * 2012-06-21 2024-02-09 西北大学 肽缀合粒子
KR20160042079A (ko) * 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
WO2017139498A1 (en) * 2016-02-09 2017-08-17 Cour Pharmaceuticals Development Company Inc. Timps encapsulating japanese cedar pollen epitopes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032625A1 (en) * 1998-12-04 2000-06-08 Biogen, Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
WO2013122262A1 (en) * 2012-02-16 2013-08-22 Vlp Therapeutics, Llc Virus like particle composition

Also Published As

Publication number Publication date
IL304580A (en) 2023-09-01
JP2023160828A (ja) 2023-11-02
JP2021143206A (ja) 2021-09-24
JP7333360B2 (ja) 2023-08-24
JP2019507113A (ja) 2019-03-14
JP7730867B2 (ja) 2025-08-28
IL260296B1 (en) 2023-09-01
WO2017120222A1 (en) 2017-07-13
CA3009799A1 (en) 2017-07-13
JP2025181835A (ja) 2025-12-11
IL260296A (en) 2018-08-30
EP3400069A4 (en) 2019-09-25
JP6904959B2 (ja) 2021-07-21
US20190365656A1 (en) 2019-12-05
EP3400069A1 (en) 2018-11-14
US20240122864A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
US20240122864A1 (en) Particles encapsulating fusion proteins containing linked epitopes
AU2020244453B2 (en) Peptide conjugated particles
US11160851B2 (en) Peptide conjugated particles
JP2014501726A (ja) Ｎｋｔ細胞によって認識されるエピトープの添加による、抗原免疫原性の調節
HK1209039B (en) Peptide conjugated particles